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Due to their role in many diseases, enzymes of the
ubiquitin system have recently become interesting
drug targets. Despite efforts, primary screenings of
compound libraries targeting E2 enzymes and E3 li-
gases have been strongly limited by the lack of
robust and fast high-throughput assays. Here we
report a label-free high-throughput screening assay
for ubiquitin E2 conjugating enzymes and E3 ligases
based on MALDI-TOF mass spectrometry. The
MALDI-TOF E2/E3 assay allows testing E2 enzymes
and E3 ligases for their ubiquitin transfer activity,
identifying E2/E3 active pairs, inhibitor potency
and specificity and screening compound libraries
in vitro without chemical or fluorescent probes. We
demonstrate that the MALDI-TOF E2/E3 assay is a
universal tool for drug discovery screening in the
ubiquitin pathway as it is suitable for working with
all E3 ligase families and requires a reduced amount
of reagents, compared with standard biochemical
assays.
INTRODUCTION
Ubiquitylation is a post-translational modification which impacts
almost every biological process in the cell. Dysregulation of the
ubiquitylation pathway is associated with several diseases,
including cancer, neurodegenerative disorders, and immunolog-
ical dysfunctions. Single ubiquitin moieties or polyubiquitin
chains are added to the substrate by the combined action of
three different classes of enzymes: the E1 activating enzymes,
the E2s conjugating enzymes, and the E3 ligase enzymes (Pick-
art, 2001). In the first step, a single ubiquitin molecule is coupled
to the active site of an E1 ubiquitin-activating enzyme in an ATP-
dependent reaction. In the second step, the ubiquitin molecule is
transferred from E1 to an E2 ubiquitin conjugating enzyme. In the
final step, ubiquitin is transferred to the protein substrate in a
process mediated by an E3 ubiquitin ligase, which provides a
binding platform for ubiquitin-charged E2 and the substrate.Cell Chemical Biology 25, 1117–1127, Septem
This is an open access article undUbiquitin chain formation is highly specific and regulated by a
plethora of different E2 conjugating enzymes and E3 ligases.
The human genome encodes two ubiquitin-activating E1, >30
ubiquitin-specific E2, and 600–700 of E3 ligases (Kim et al.,
2011). Thus, including about 100 deubiquitylating enzymes,
approximately 800 ubiquitin enzymes regulate the dynamic ubiq-
uitylation of a wide range of protein substrates (Kim et al., 2011).
Within this complexity, E3 ligases are the most diverse class of
enzymes in the ubiquitylation pathway as they play a central
role in determining the selectivity of ubiquitin-mediated protein
degradation and signaling.
E3 ligases have been associated with a number of pathogenic
mechanisms. Mutations in the E3 ligases MDM2, BRCA1,
TRIMs, and Parkin have been linked to multiple cancers and
neurodegenerative diseases (Fakharzadeh et al., 1991; Hata-
keyama, 2011; Welcsh and King, 2001), and MDM2-p53 interac-
tion inhibitors have already been developed as a potential anti-
cancer treatment (Shangary and Wang, 2009). This highlights
the potential of E2 enzymes and E3 ligases as drug targets.
Although all E3 ligases are involved in the final step of covalent
ubiquitylation of target proteins, they differ in both structure
and mechanism and can be classified in three main families de-
pending on the type of E3 ligases promoting ubiquitin-protein
ligation and on the presence of characteristic domains. The
RING ligases bring the ubiquitin-E2 complex into the molecular
vicinity of the substrate and facilitate ubiquitin transfer directly
from the E2 enzyme to the substrate protein. In contrast, homol-
ogous to the E6-AP C terminus family (HECTs) covalently bind
the ubiquitin via a cysteine residue in their catalytic HECT domain
before shuttling it onto the target molecule. RING between
RINGs (RBRs) E3 ligases were shown to use both RING- and
HECT-like mechanisms where ubiquitin is initially recruited on
a RINGdomain (RING1) then transferred to the substrate through
a conserved cysteine residue in a secondRINGdomain. The vast
majority of human E3 enzymes belong to the RING family, while
only 28 belong to the HECT and 14 to the RBR family of E3 li-
gases (Chaugule and Walden, 2016).
Due to the high attractiveness of E2 and E3 ligases as drug
targets, a number of drug discovery assays have been pub-
lished, based on detection by fluorescence (Dudgeon et al.,
2010; Krist et al., 2016; Zhang et al., 2004), antibodies (Davydov
et al., 2004; Huang et al., 2005; Kenten et al., 2005; Marblestone
et al., 2010), tandem ubiquitin-binding entities (Heap et al.,ber 20, 2018 ª 2018 The Authors. Published by Elsevier Ltd. 1117
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2017a; Marblestone et al., 2012), surface plasmon resonance
(Regnstrom et al., 2013), or cellular and bacterial two-hybrid
(Levin-Kravets et al., 2016; Maculins et al., 2016). However,
many of these tools are either too expensive for very high-
throughput drug discovery or potentially result in false-positive
and false-negative hits due to the use of non-physiological E2/
E3 ligase substrates. We have addressed this gap by developing
the first in vitro label-free MALDI-TOFmass spectrometry-based
approach to screen the activity of E2 and E3 ligases that uses un-
modified mono-ubiquitin as substrate. As a proof-of-concept,
we screened a collection of 1,430 US Food and Drug Administra-
tion (FDA)-approved drugs for inhibitors of a subset of three E3
ligases that are clinically relevant and belong to three different
E3 ligase families. The screen shows high reproducibility and
robustness, and we were able to identify a subset of 15 mole-
cules active against the E3 ligases tested. We validated the
most powerful positive hits by determining the half maximal
inhibitory concentration (IC50) values against their targets,
confirming that bendamustine and candesartan cilexitel inhibit
HOIP and MDM2, respectively, in in vitro conditions.
RESULTS
MALDI-TOF E2-E3 Assay Rational and Development
E2 and E3 ligase activity results in formation of free or
attached polyubiquitin chains, mono-ubiquitylation, and/or mul-
tiple mono-ubiquitylation of a specific substrate. However, in
absence of a specific substrate, most E3 ligases will either pro-
duce free polyubiquitin chains or undergo auto-ubiquitylation
which is a mechanism thought to be responsible for the regula-
tion of the E3 enzyme itself (de Bie and Ciechanover, 2011).
Furthermore, there is some evidence that auto-ubiquitylation of
E3 ligases is facilitating the recruitment of the E2 ubiquitin conju-
gating enzyme (Ranaweera and Yang, 2013). Auto-ubiquitylation
assays or free polyubiquitin chain production have been widely
used to assess the E3 ligase potential of a protein (de Bie and
Ciechanover, 2011; Lorick et al., 1999). We used this property
of E2 and E3 ligases to design a MALDI-TOF mass spectrom-
etry-based high-throughput screening (HTS) method that al-
lowed the reliable determination of activities of E2 and E3 ligase
pairs by measuring the depleting intensity of mono-ubiquitin in
the assay as a readout.
As proof-of-concept we used three E3 ligases belonging to
different E3 families and representative of all the currently known
ubiquitylation mechanisms. MDM2 is an RING-type E3 ligase
which controls the stability of the transcription factor p53, a
key tumor suppressor that is often found mutated in human can-
cers (Rivlin et al., 2011; Vogelstein et al., 2000). ITCH belongs to
the HECT domain-containing E3 ligase family involved in theFigure 1. The MALDI-TOF E2/E3 Ligase Assay
(A) Workflow of the MALDI-TOF E2/E3 assay. Each of the three E3 ligases were i
(12.5, 6.25, and 3.125 mM) at 37C. Reactions were stopped by addition of 2.5 mL 1
weremixed with 150 nL of 1.5 mM 15N ubiquitin as internal standard. Subsequently
onto a 1,536 AnchorChip MALDI target (Bruker Daltonics). Data analysis was pe
(B) E2/E3 ligase reactions are linear. Linearity is determined by mono-ubiquitin co
reaction is not linear. Data points have been normalized to determine reaction lin
(C) Western blots of in vitro reactions (E1 100 nM, UBE2D1 250 nM, UBE2L3 125 n
E3 ligases showing increased ubiquitin chain formation over time.regulation of immunological response and cancer development
(Hansen et al., 2007; Rivetti di Val Cervo et al., 2009; Rossi
et al., 2009). Finally, HOIP, an RBR E3 ubiquitin ligase and mem-
ber of the LUBAC (linear ubiquitin chain assembly complex). As
part of the LUBAC complex, HOIP is involved in the regulation of
important cellular signaling pathways that control innate immu-
nity and inflammation through nuclear factor nuclear factor kB
(NF-kB) activation and protection against tumor necrosis factor
a-induced apoptosis (Kirisako et al., 2006; Tokunaga et al.,
2009). HOIP is the only known E3 ligase generating linear ubiqui-
tin chains (Ikeda et al., 2011). Because of that, fluorescent as-
says using C- or N-terminally labeled ubiquitin species cannot
be used to form linear chains.
To determine MDM2, ITCH, and HOIP auto-ubiquitylation re-
action rate and the linearity range we followed the consumption
of mono-ubiquitin over time with increasing starting amount of
mono-ubiquitin. We matched MDM2, ITCH, and HOIP with E2
conjugating enzymes as reported in the literature: MDM2 and
ITCH were incubated with E2D1 (UbcH5a) (Honda et al., 1997),
while HOIP was used in combination with UBE2L3 (UbcH7) (Kir-
isako et al., 2006). In brief, the in vitro ubiquitylation reaction con-
sisted of 1 mM ATP, 12.5, 6.25, and 3.125 mM ubiquitin, 50 nM
E1, 250 nM E2, and 250 or 500 nM E3 ligase enzyme at 37C
for 30 min in a total volume of 5 mL (Figure 1A). Reactions were
started by addition of ubiquitin and terminated by addition of
2.5 mL of 10% (v/v) trifluoroacetic acid. A dose of 1.05 mL of
each reaction was then spiked with 300 nL (4 mM) of 15N-labelled
ubiquitin and 1.2 mL of 2,5-dihydroxyacetophenone matrix and
250 nL of this solution was spotted onto a 1,536 mL plate MALDI
anchor target using a nanoliter dispensing robot. The samples
were analyzed by high mass accuracy MALDI-TOF mass spec-
trometer (MS) in reflector positive ion mode on a rapifleX
MALDI-TOF MS.
Importantly, the use of 15N-labeled ubiquitin as internal stan-
dard allowed us not only to avoid spot-to-spot and shot-to-
shot variability in MALDI ionization (Ritorto et al., 2014), but
also it allowed us to keep track of the amount of mono-ubiquitin
‘‘consumed’’ during the assay. Overall, this setup allowed us to
achieve very high precision, accuracy and reproducibility of
measurements.
In our experimental conditions, ubiquitin consumption relied
on the presence on an E3 ligase as we did not observe a
significant reduction in the ubiquitin level within the negative
controls (Figure 1B), where only E1 activating enzyme and E2
conjugating enzyme were present. Enzyme concentrations
were optimized by reducing enzyme concentrations of previ-
ously reported SDS-PAGE auto-ubiquitylation assay protocols
(Choo and Zhang, 2009; Zhao et al., 2012). An excess of ubiquitin
(in the mM range) compared with the ubiquitin cascade enzymesncubated with their E2 partner with different concentrations of mono-ubiquitin
0% trifluoroacetic acid (TFA) at different time points. Reaction aliquots (1.05 mL)
, the analytes weremixed with 2,5-dihydroxyacetophenonematrix and spotted
rformed using FlexAnalysis.
nsumption over time. Only at very high and low concentrations of ubiquitin, the
earity. Data are represented as mean ± SD.
M, MDM2 and ITCH 500 nM, HOIP 250 nM, and ubiquitin 6.25 mM) of the three
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Figure 2. Characterizing E2 Enzyme In Vitro
Activity
Twenty-seven E2 enzymes were incubated at three
different concentrations (250, 500, and 1,000 nM)
with the E1 UBE1 and 6.125 mM ubiquitin at 37C.
Reactions were stopped at the indicated time
points with 2% TFA final and analyzed by MALDI-
TOF mass spectrometry. Ligase activity was
calculated considering T0 as 0% and the complete
disappearance of mono-ubiquitin from the win-
dows signal as 100% activity.(250 nM for HOIP, 500 nM for ITCH, and 500 nM for MDM2) was
found necessary in order to control reaction velocity. As ex-
pected, we observed that ubiquitin consumption was dose and
enzyme dependent (Figure 1B, Figures S1 and S2). Reaction
rates were related to ubiquitin concentration (Table S1) and
different enzymes showed different rates of ubiquitin consump-
tion (Figure 1B).
The well-established E2-E3 auto-ubiquitylation assays fol-
lowed by SDS-PAGE and western blot analysis provided similar
results, and we observed that the time-dependent disappear-
ance of ubiquitin is comparable using both techniques (Fig-
ure 1C). Moreover, while substrate and enzyme concentrations
are comparable with western blot-based approaches, the reac-
tion volume (5 mL) is smaller than most of the antibody-based
approaches currently reported in literature (Sheng et al., 2012).
Determining In Vitro Activities of E2 Enzymes
E2 ubiquitin conjugating enzymes are the central players in the
ubiquitin cascade (Stewart et al., 2016). The human genome en-
codes 40 E2 conjugating enzymes, of which about 30 conju-
gate ubiquitin directly while others conjugate small ubiquitin-
like proteins such as SUMO1 and NEDD8 (Cappadocia and
Lima, 2017). E2 enzymes are involved in every step of the ubiq-
uitin chain formation pathway, from transferring the ubiquitin to
mediating the switch from ubiquitin chain initiation to elongation,
and defining the type of chain linkage. Connecting ubiquitin mol-1120 Cell Chemical Biology 25, 1117–1127, September 20, 2018ecules in a defined manner by modifying
specific Lys residues with ubiquitin is
another intrinsic property of many E2
enzymes. Early studies showed that, at
high concentrations, E2 enzymes can syn-
thesize ubiquitin chains of a distinct link-
age or undergo auto-ubiquitylation even
in the absence of an E3 (Pickart and
Rose, 1985), albeit at lower transfer rates
(Stewart et al., 2016). This characteristic
has been exploited for the generation of
large amounts of different ubiquitin chain
types in vitro (Faggiano et al., 2016).
As control for E2 enzyme mono
or multi-ubiquitylation or E2-dependent
ubiquitin chain assembly, we firstly as-
sessed which E2 conjugating enzymes
in our panel were able to consume ubiqui-
tin even in absence of a partner E3 ligase.
Utilizing the MALDI-TOF E2-E3 assay, wesystematically tested 27 recombinantly expressed E2 conju-
gating enzymes (Table S2) for their ability to process ubiquitin
either by the formation of polyubiquitin chains or by auto-ubiq-
uitylation at different concentrations (250 nM, 500 nM, and
1 mM). We found that the UBE2Q1 and UBE2Q2 were able to
consume ubiquitin even in absence of a specific E3 ligase at
250 nM after 45 min incubation time, and almost completely ex-
hausting the starting ubiquitin amount after 2 hr of incubation
(Figure 2). UBE2O and UBE2S are able to consume ubiquitin
when present at a starting concentration of 500 nM, with con-
sumption being evident from 90 min onward. Interestingly,
UBE2Q1, UBE2Q2, and UBE2O (Berleth and Pickart, 1996;
Klemperer et al., 1989; Melner et al., 2006) are E2 conjugating
enzymes characterized by an unusually high molecular mass
compared with other E2 enzymes: in particular, UBE2O has
been reported as an E2-E3 hybrid which might explain its ability
to form ubiquitin chains in the absence of an E3 ligase. Most of
the E2 conjugating enzymes showed ubiquitin-consuming activ-
ity once their concentration was increased to 1 mM. Interest-
ingly, UBE2D1 and UBE2L3 do not show any ligase activity,
even at 1 mM, making these E2 conjugating enzymes the perfect
candidates for inhibitor screening of E3 ligases as all ubiquitin-
consuming activity in an assay will be down to E3 activity. Our
results demonstrate that the E2-E3 MALDI-TOF assay has the
potential to be employed for measuring E2 in vitro activity and
therefore can be employed for screening inhibitors against
Figure 3. Characterizing E2/E3 Pair
Activities
E1-E2 enzymes (50 and 250 nM, respectively)
and E3 ligases were incubated in duplicate with
6.125 mM ubiquitin at 37C for the time indicated.
Reactions were stopped at the indicated time
points with 2% TFA final and analyzed by MALDI-
TOF mass spectrometry. Ligase activity was
calculated considering T0 as 0% and the complete
disappearance of mono-ubiquitin signal from the
mass window as 100% activity.those E2 enzymes that possess intrinsic ubiquitin ligase activity
in vitro.
Determining E2/E3 Active Pairs
Any given E3 ligase cooperates with specific E2 enzymes in vivo.
However, it is still difficult to predict which E2/E3 enzyme pair
would be functional. Determining E2/E3 specificity is paramount
to set up in vitro ubiquitylation assays and to perform inhibitor
screens against E3 ligases. Using the E2/E3 MALDI-TOF
assay, we investigated the activity of MDM2, ITCH, and HOIP
throughout 8 time points when incubated with any of 27 ubiquitin
E2 enzymes, covering the majority of the reported classes/fam-
ilies (Figure 3). We arbitrarily defined ‘‘fully active’’ pairs any E2-
E3 couple that completely depleted the mono-ubiquitin starting
amount after 2 hr incubation time. The UBE2D family is reported
in the literature as being able to productively interact with MDM2
(Marblestone et al., 2013), ITCH (Sheng et al., 2012), and HOIP
(Lechtenberg et al., 2016). Our data showed that UBE2D1 and
UBE2D2, also known as UBCH5a and UBCH5b, were fully active
with all the E3 ligases under investigation confirming the promis-
cuous activity of this class of E2 enzymes that was previously re-
ported in the literature (Lechtenberg et al., 2016; Marblestone
et al., 2013; Sheng et al., 2012). The UBE2E family was only
partially active against the E3s ligases of interest. The well-char-
acterized human E2L3 (or UBCH7) showed activity with HOIP
and ITCH, confirming the already reported UBCH7 ability ofCell Chemical Biologyfunctioning with both HECT and RBR E3
families (Capili et al., 2004; Shimura
et al., 2000). Taken together these results
demonstrate that the E2/E3 MALDI-TOF
assay is suitable for determining E2 spec-
ificity toward their cognate E3 enzymes in
a high-throughput fashion.
Assessing Potency and Selectivity
of E2/E3 Inhibitors
We next evaluated whether the MALDI-
TOF E2/E3 assay had the potential to
assess the potency and selectivity of
E2/E3 inhibitors. As proof-of-concept,
we tested five inhibitors that had previ-
ously been reported to inhibit E1, E2, or
E3 ligases: PYR41 (Yang et al., 2007),
BAY117082 (Strickson et al., 2013), glio-
toxin (Sakamoto et al., 2015), nutlin-3A
(Vassilev et al., 2004), clomipramine(Rossi et al., 2014), and Compound 1 (Brownell et al., 2010).
We also tested PR619 (Altun et al., 2011), a broad-spectrum, al-
kylating deubiquitylase (DUB) inhibitor, which we hypothesized
would also inhibit other enzymes with active site cysteines,
such as E1/E2 enzymes and E3 ligases. PYR41 is a specific
and cell-permeable inhibitor of E1 ubiquitin loading but does
not directly affect E2 activity (Yang et al., 2007). BAY117082,
initially described as inhibitor of NF-kB phosphorylation, has
been shown to inactivate the E2 conjugating enzymes Ubc13
(UBE2N) and UBCH7 (UBE2L3), as well as the E3 ligase LUBAC
(of which HOIP is part) (Strickson et al., 2013). Gliotoxin is a
fungal metabolite identified as a selective inhibitor of HOIP
through an fluorescence resonance energy transfer (FRET)-
based HTS assay (Sakamoto et al., 2015). Nutlin 3A is a
MDM2-p53 interaction inhibitor, able to displace p53 from
MDM2 with an IC50 in the 100–300 nM range (Khoury and Dom-
ling, 2012). However nutlins are not reported to be able to inhibit
MDM2 auto-ubiquitylation. Compound 1 is a pan-inhibitor of
ubiquitin-like activating enzymes, an analog of the NEDD8 acti-
vating enzyme inhibitor MLN4924 (Rossi et al., 2014; Soucy
et al., 2009). It forms a covalent adduct with the ubiquitin-like
substrate through its sulfamate group in a process that requires
Mg-ATP. Clomipramine is a compound reported as able to
block ITCH ubiquitin transthiolation in an irreversible manner,
achieving complete inhibition at 0.8 mM (Rossi et al., 2014).
However, in our hands it did not inhibit any of the E3 ligases at25, 1117–1127, September 20, 2018 1121
(legend on next page)
1122 Cell Chemical Biology 25, 1117–1127, September 20, 2018
Figure 5. High-Throughput E2/E3 MALDI-
TOF Screen
A total of 1,430 compounds from various com-
mercial suppliers were tested at a final concen-
tration of 10 mM each against MDM2, ITCH, and
HOIP. The uninhibited control contained 5 nL
DMSO but no compound, whereas the inhibited
control had been inactivated by pre-treatment with
2.0% TFA.10 mM, and we determined its IC50 for ITCH to be 500 mM (Fig-
ure S3). We therefore did not follow up clomipramine.
Performing IC50 inhibition curves using the MALDI-TOF E2/E3
assay (Figure 4; Table S3), we could show that PYR41 inhibited
MDM2, ITCH, and HOIP at IC50 values of 3.1, 11.3, and 5.7 mM.
BAY117082 also strongly inhibited MDM2 with an IC50 value
of 2.4 mM, and HOIP and ITCH with IC50 values of 2.9
and 25.9 mM, respectively. Gliotoxin showed an IC50 value of
2.8 mM against HOIP, of 30.5 mM against ITCH, and 0.5 mM
against MDM2. As expected, nutlin-3A did not show any inhibi-
tory activity toward MDM2, ITCH, or HOIP, as it was designed
as an interaction inhibitor. We found that Compound 1 inhibited
the reactions with all three E3 ligases with similar potencies at
1–2 mM, probably by inhibiting the E1 enzyme. PR619 resulted
as the most powerful inhibitor of the ubiquitination cascade,
with an IC50 of 0.6 mM against MDM2, 0.4 mM against ITCH,
and 0.2 mM when tested against HOIP, suggesting that PR619,
which also acts as a DUB inhibitor (Ritorto et al., 2014), has a
very low degree of selectivity and inhibits many enzymes with
active cysteines.
To test if these compounds can covalently modify E2 en-
zymes, we used MALDI-TOFMS of the intact proteins incubated
with the inhibitor compounds. We found that BAY117082
and PR619 both covalently modified E2 enzymes (Figure S4).
BAY117082 has been previously characterized for its ability to
bind to a cysteine of UBE2N resulting in a mass shift of 51 Da
(Strickson et al., 2013). Here we observed that BAY117082 cova-
lently bound to UBE2L3 resulting in a mass shift of 153 Da, cor-
responding to the addition of three molecules of BAY117082 to
the three cysteines encoded within its sequence. The covalent
binding of multiple BAY117082 and PR619 molecules to the E2
might explain the high values for the Hill coefficients (see Table
S4) when performing IC50 curves. We also would like to point
out that we noticed that the initial presence of b-mercaptoetha-
nol (BME) in the MDM2 preparation suppressed the inhibition
effect of PYR41 and BAY117082. Removal of BME showed the
inhibition as presented in Figure 4. We therefore recommend
avoiding thiol-based reducing agents such as BME or DTT
when testing compounds that target active cysteines which
are present in most of the ubiquitin pathway enzymes. Both of
these reducing agents can be replaced with (tris(2-carbox-
yethyl)phosphine.Figure 4. IC50 Analyses of six inhibitors for Selected E3 Ligases
IC50 determination for six described E3 ligase inhibitors for MDM2 (A), ITCH (B)
different concentrations (0–100 mM). Ubiquitin was added and incubated for a ran
Prism GraphPad software was used with a built-in analysis, nonlinear regression (
are represented as mean ± SD.Overall, our results demonstrate that the MALDI-TOF E2-E3
assay is suitable for comparing inhibitor potency through IC50
determination.
E2/E3 Assay by MALDI-TOF Is Suitable for HTS
Having established that the E2/E3 MALDI-TOF assay can be
used to assess the specificity and potency of inhibitors, we
explored its suitability for HTS. It is important to underline that,
because of the nature of the assay, inhibitors of E1 or E2, which
both contain active site cysteines (Rossi et al., 2014; Sakamoto
et al., 2015) may be identified as hits. We tested a library of 1,430
FDA-approved compounds from various commercial suppliers
with validated biological and pharmacological activities at
10 mM final. None of the compounds present in the library are
known for specifically targeting MDM2, ITCH, or HOIP. The
assay was performed supplying ATP in excess (1 mM) to reduce
the likelihood of identifying ATP analogs as inhibitors of these
enzymes.
The screens against the three different E3 ligases, expressed
as percentage effect (Figures 5 and S5) exhibited robust Z0
scores >0.5 (Table S5). These scores provide a measure for
the suitability of screening assays; HTS assays that provide Z0
scores >0.5 are generally considered robust.
We defined as a positive hit a compound whose potency
ranked above the 50% residual activity threshold. Overall, we
identified nine compounds reporting inhibition rates >50%
against the E3 ligases of interest. Candesartan cilexetil was
the only compound able to inhibit MDM2 activity by more
than 50% (see Table 1). With regard to HOIP screening, six
compounds were identified as potential inhibitors: bendamus-
tine, moclobemide, ebselen, cefatrizine, fluconazole, and pyra-
zinamide. The ITCH inhibitor screening identified two positive
hits: hexachlorophene and ethacrynic acid. Hexachlorophene
is an organochloride compound once widely used as a disin-
fectant. It acts as an alkylating agent, thus resulting in the
wide and not specific inhibition of E3 ligases: this explains
why this compound results as a weak inhibitor of MDM2 as
well. Ethacrynic acid is a diuretic compound (Melvin et al.,
1963) and a potent inhibitor of glutathione S-transferase, with
intrinsic chemical reactivity toward sulfhydryl groups (Koechel,
1981), which might explains its ranking as positive hit in our
assay when tested against both MDM2 and ITCH. Overall,, and HOIP (C). Small inhibitor compounds were pre-incubated for 30 min at
ge of time depending on the E3 (usually 30 or 40 min). For statistical analysis,
curve-fit), variable slope (four parameters) curve to determine IC50 values. Data
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Table 1. Positive Hits Identified by E2/E3 MALDI-TOF Assay
E2/E3 Ligase Compound Name
Residual
Activity (%)
UBE1/UBE2L3/
HOIP
bendamustine 6.3
moclobemide 25.9
ebselen 36.2
fluconazole 46.4
cefatrizine 49.0
pyrazinamide 49.3
nevirapine 54.8
resveratrol 62.2
bupivacaine 66.2
2-(3,4-dimethoxyphenyl)
ethanamine
68.2
UBE1/UBE2D1/
ITCH
hexachlorophene 22.2
ethacrynic acid 29.5
alosetron 58.2
vecuronium or pancuronium 67
UBE1/UBE2D1/
MDM2
candesartan cilexetil 48.6
hexachlorophene 52.4
ethacrynic acid 53.9
aztreonam 56.7our results demonstrate that the E2/E3 MALDI-TOF assay can
be employed to screen large compound libraries against E1,
E2 conjugating enzymes and E3 ligases belonging to different
families for the identification of new inhibitors in the ubiquitin
pathway.
Validation of Positive Hits
To validate the results obtained from the HTS we performed IC50
determination of compounds with the highest inhibitor potency
in the single point screening. Candesartan cilexitel, an angio-
tensin II receptor antagonist, inhibited MDM2 with an IC50 of
8.8 mM (Figure 6A). Best hit was bendamustine, a nitrogen
mustard used in the treatment of chronic lymphocytic leukemia
and lymphomas. It belongs to the family of alkylating agents.
Bendamustine ranked as the compound with the highest inhibi-
tion score against HOIP, while it did not significantly affect
MDM2 and ITCH activities. We confirmed that bendamustine
selectively inhibited HOIP at an IC50 of 6.4 mM, while ITCH and
MDM2 showed a considerably higher IC50 value of 76.8 mM
and 114 mM, respectively (Figure 6B). Bendamustine retained
its inhibition power when HOIP was paired with UBE2D1 as
conjugating enzyme (Figure S6), suggesting that the compound
binds preferentially to HOIP. This shows that theMALDI-TOF E2/
E3 ligase assay can be used to identify selective inhibitors from a
high-throughput screen.
DISCUSSION
The ubiquitin system has in recent years become an exciting
area for drug discovery (Cohen and Tcherpakov, 2010), as
multiple enzymatic steps within the ubiquitylation process are
druggable. The potential of targeting the ubiquitin-proteasome1124 Cell Chemical Biology 25, 1117–1127, September 20, 2018pathway was first demonstrated in 2003 by the approval
of the proteasome inhibitor bortezomib (Velcade; Millennium
Pharmaceuticals) for use in multiple myeloma. While protea-
some inhibition is a broad intervention affecting general surviv-
ability, E3 ubiquitin ligases and DUBs (Ritorto et al., 2014)
represent the most specific points of intervention for therapeu-
tic tools as they specifically regulate the ubiquitylation rate of
specific substrates. For example, nutlins, cis-imidazoline ana-
logs able to inhibit the interaction between MDM2 and tumor
suppressor p53, have recently entered early clinical trials for
the treatment of blood cancers (Burgess et al., 2016). The small
number of drugs targeting E3 ligases currently on the market is
partly due to the lack of suitable high-throughput assays for
drug discovery screening. Traditionally, screening for inhibitors
of ubiquitin ligases and DUBs has been performed using
different fluorescence-based formats in high-throughput and
ELISA, SDS-PAGE, and western blotting in low-throughput.
These approaches show a number of limitations. ELISA- and
SDS-PAGE-based approaches are time consuming and low-
throughput by nature, and therefore mostly incompatible with
HTS. The applicability of fluorescence-based techniques such
as FRET is dependent on being able to get FRET donors and
acceptors in the right distance, and the fluorescent label might
affect inhibitor binding. To address these issues, we have
developed a sensitive and fast assay to quantify in vitro E2/
E3 enzyme activity using MALDI-TOF MS. It builds on our
DUB MALDI-TOF assay (Ritorto et al., 2014), which has enabled
us to screen successfully for a number of selective DUB inhib-
itors (Kategaya et al., 2017; Magiera et al., 2017; Weisberg
et al., 2017), and adds to the increasing number of drug discov-
ery assays utilizing label-free high-throughput MALDI-TOF MS.
Apart from E2/E3 enzymes and DUBs (Ritorto et al., 2014),
high-throughput MALDI-TOF MS has now successfully been
used for drug discovery screening of protein kinases (Heap
et al., 2017b), protein phosphatases (Winter et al., 2018), his-
tone demethylases, and acetylcholinesterases (Haslam et al.,
2016), as well as histone lysine methyltransferases (Guitot
et al., 2014).
Unlike other current assays, all these label-free MALDI-TOF
MS methods use unmodified substrates, such as mono-ubiqui-
tin. The advantages compared with fluorescence or antibody-
based high-throughput assays is the ability to work with en-
zymes without the previous development of specific chemical/
fluorescent probes, as well as the reduced consumable costs
for the assay as no antibodies are required. Moreover, because
of the sensitivity of current MALDI-TOF MSs, all enzymes are
usually kept at low concentrations thereby significantly reducing
the amounts and cost per assay.
In the context of E3 ligase drug discovery, it is critical to iden-
tify the appropriate E2/E3 substrate pairing to ensure the devel-
opment and use of the most physiologically relevant screening
assay. There have been many reports of limited E2/E3 activity
profiling with a small number of E2 and E3 enzymes using
ELISA-based assays, structural-based yeast two-hybrid as-
says, and western blot (Lechtenberg et al., 2016; Marblestone
et al., 2013; Sheng et al., 2012). All of these approaches
are time consuming, require large amounts of reagents, and
are difficult to adapt for HTS. We have successfully used our
E2/E3MALDI-TOF assay to identify active E2/E3 pairings, which
Figure 6. Validation of Hits
(A) Candesartan Cilexetil shows an IC50 of 8.8 mM
against MDM2.
(B) Bendamustine shows some specificity for HOIP
(IC50 = 6.3 mM) while inhibiting MDM2 (IC50 =
114 mM) and ITCH (IC50 = 76.8 mM) at higher con-
centrations. Data are represented as mean ± SD.could then be further characterized using our HTS screen. The
‘‘E2 scan’’ was quickly and easily adapted, collecting data of
three E3 enzymes against 29 E2 enzymes at 8 time points in
one single experiment. Moreover, after identification of the right
E2/E3 pairs, we applied the MALDI-TOF E2/E3 assay to deter-
mine inhibition rates and the IC50 values of small-molecule in-
hibitors. In a proof-of-concept study, we performed an HTS
for inhibitors of three E3 ligases. The MALDI-TOF analysis
speed of 1.3 s per sample (35 min per 1,536-well plate) and
low sample volumes (reaction volume 5 mL/MALDI deposition
250 nL) make the E2/E3 MALDI-TOF assay comparable with
other fluorescence/chemical probe-based technologies. Auto-
matic sample preparation, MALDI-TOF plate spotting, and
data collection allowed us to quickly analyze thousands of
compounds through the use of 1,536 sample targets. The assay
successfully identified bendamustine as a novel small-molecule
inhibitor for HOIP, an attractive drug target for both inflamma-
tory disease and cancer (Ikeda et al., 2011; MacKay et al.,
2014; McGuire et al., 2016; Stieglitz et al., 2013). Bendamustine,
a nitrogen mustard, shows likely very high reactivity against a
range of targets in the cell including its intended target DNA.
However, it is surprising that it shows a 12- and 18-fold higher
activity against HOIP than against ITCH and MDM2, respec-
tively, suggesting that there is possibly a structural effect and
some selectivity can be reached between different E3 ligases.
It also shows that E1 conjugating enzymes were not affected
by bendamustine as the same enzyme was also used in the
MDM and ITCH reaction. While this is just a proof-of-concept
study characterizing E2/E3 activity and identifying inhibitors in
an in vitro system, follow-up studies will need to verify results
in cellular and ultimately in vivo models.
In conclusion, we present here a novel screening method to
assay E2/E3 activity with high sensitivity, reproducibility, and
reliability, which is able to carry out precise quantified measure-
ments at a rate of1 s per sample spot. Using physiological sub-
strates, we showed proof-of concept for three E3 ligases that are
attractive drug targets. Considering the speed, low consumable
costs, and the simplicity of the assay, the MALDI-TOF E3 ligase
assay will serve as a sensitive and fast tool for screening for E1,
E2 enzyme, and E3 ligase inhibitors.Cell Chemical BiologySIGNIFICANCE
Our understanding of the ubiquitin
biology has been rapidly expanding.
The role of the ubiquitin system in the
pathogenesis of numerous disease
states has increased the interest in
finding new strategies to pharmaco-
logically interfere with the enzymes
responsible of the ubiquitination pro-cess. However, the development of molecules targeting
the ubiquitin cascade, especially the E2 conjugating en-
zymes and E3 ligases, has not being extensively sustained
by the availability of robust and affordable technologies for
extensive primary screening of compound libraries. Per-
forming high-throughput screening in the ubiquitin field re-
mains challenging and it usually requires engineered pro-
teins or the synthesis of chemical probes. Here we show
that the MALDI-TOF E2-E3 assay is a robust, scalable, la-
bel-free assay that can be employed for primary screening
of compound libraries against E2 conjugating enzymes
and E3 ligases belonging to different families and represen-
tative of all the currently known ubiquitylation mechanisms.
The MALDI-TOF E2/E3 assay is a readily accessible addition
to the drug discovery toolbox with the potential to accel-
erate drug discovery efforts in the ubiquitin pathway.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant Proteins
Ubiquitin Monomer Sigma Aldrich U6253
HOIP MRC PPU Reagents Q00987
ITCH MRC PPU Reagents Q96J02
MDM2 MRC PPU Reagents Q96EP0
UBE1 MRC PPU Reagents P22314
UBA6 MRC PPU Reagents A0AVT1
UBE2A MRC PPU Reagents P49459
UBE2B MRC PPU Reagents P63146
UBE2C MRC PPU Reagents O00762
UBE2D1 MRC PPU Reagents P51668
UBE2D2 MRC PPU Reagents P62837
UBE2D3 MRC PPU Reagents P61077
UBE2D4 MRC PPU Reagents Q9Y2X8
UBE2E1 MRC PPU Reagents P51965
UBE2E2 MRC PPU Reagents Q96LR5
UBE2E3 MRC PPU Reagents Q969T4
UBE2G1 MRC PPU Reagents P62253
UBE2G2 MRC PPU Reagents P60604
UBE2H MRC PPU Reagents P62256
UBE2J1 MRC PPU Reagents Q9Y385
UBE2J2 MRC PPU Reagents Q8N2K1
UBE2K MRC PPU Reagents P61086
UBE2L3 MRC PPU Reagents P68036
UBE2N MRC PPU Reagents P61088
UBE2O MRC PPU Reagents Q9C0C9
UBE2Q1 MRC PPU Reagents Q7Z7E8
UBE2Q2 MRC PPU Reagents Q8WVN8
UBE2R1 MRC PPU Reagents P49427
UBE2R2 MRC PPU Reagents Q712K3
UBE2S MRC PPU Reagents Q16763
UBE2T MRC PPU Reagents Q9NPD8
UBE2V1 MRC PPU Reagents Q13404
UBE2W MRC PPU Reagents Q96B02
UBE2Z MRC PPU Reagents Q9H832
Chemicals
2,5-Dihydroxyacetophenone Bruker Daltonics 8231829
Clomipramine Sigma Aldrich C7291
Bendamustine Sigma Aldrich B5437
Gliotoxin Sigma Aldrich G9893
BAY-11-7082 Sigma Aldrich B5556
PYR-41 Sigma Aldrich N2915
PR-619 Millipore 662141
Compound library of 1430 FDA approved drugs DDU
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding authors
Virginia De Cesare (v.decesare@dundee.ac.uk), Matthias Trost matthias.trost@ncl.ac.uk). PYR41 and Nutlin3A were kindly provided
by Sara Buhrlage, PhD, Dana Farber Cancer Institute. Compound1 was kindly provided by Satpal Virdee, PhD, MRC-PPU Dundee.
Plasmids generated at the University of Dundee for the present study are available to request on our reagents website (https://
mrcppureagents.dundee.ac.uk/).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ubiquitin monomer, BSA, Tris, DTT and Gliotoxin were purchased from Sigma-Aldrich. MALDI TOFMSmaterials (targets, matrix and
protein calibration mixture) were purchased from Bruker Daltonics (Bremen, Germany). PYR41 and Nutlin3A compounds were kindly
provided by Sara Buhrlage (Dana-Farber Cancer Institute) and Compound-1 was kindly provided by Satpal Virdee (MRC PPU,
Dundee).
E1, E2, ITCH and HOIP E3 Enzyme Expression and Purification
15N-labelled ubiquitin was produced as described in Ritorto et al (Ritorto et al., 2014). Human recombinant 6His-tagged UBE1 was
expressed in and purified from Sf21 cells using standard protocols. Human E2s were all expressed as 6His-tagged fusion proteins in
BL21 cells and purified via their tags using standard protocols. Briefly, BL21 DE3 codon plus cells were transformed with the appro-
priate constructs (see table below), colonies were picked for overnight cultures, which were used to inoculate 6 x 1L LBmedium sup-
plemented with antibiotics. The cells were grown in Infors incubators, whirling at 200 rpm until the OD600 reached 0.5 – 0.6 and then
cooled to 16C – 20C. Protein expression was induced with typically 250 mM IPTG and the cells were left over night at the latter tem-
perature. The cells were collected by centrifugation at 4200 rpm for 25min at 4C in a Beckman J6 centrifuge using a 6 x 1 L bucket
rotor (4.2). The cells were resuspended in ice cold lysis buffer (50mMTris-HCl pH 7.5, 250mMNaCl, 25mM imidazole, 0.1mMEGTA,
0.1 mM EDTA, 0.2 % Triton X-100, 10 mg/ml Leupeptin, 1 mM PefaBloc (Roche), 1mM DTT) and sonicated. Insoluble material was
removed by centrifugation at 18500 xg for 25 min at 4C. The supernatant was incubated for 1 h with Ni-NTA-agarose (Expedeon),
then washed five times with 10 volumes of the lysis buffer and then twice in 50 mM HEPES pH 7.5, 150 mM NaCl, 0.015% Brij35,
1 mM DTT. Elution was achieved by incubation with the latter buffer containing 0.4M imidazole or by incubation with Tobacco
Etch Virus (TEV) protease (purified in house). The proteins were buffer exchanged into 50 mM HEPES pH 7.5, 150 mM NaCl, 10%
glycerol and 1 mM DTT and stored at -80C. HOIP (697-1072) DU22629 and Itch (DU11097) ligases were expressed in BL21 cells
as GST-tagged fusion proteins, purified via their tag and collected by elution (GST-Itch) or by removal of the GST-tag on the
resin (HOIP).
MDM2 E3 Enzyme Expression and Purification
pGex-Mdm2 [DU 43570] was expressed in BL21 (DE3) E. coli cells grown in LB media containing 100 mg/ml ampicillin. Cells were
induced with 250 mM isopropyl beta-D-1-thiogalactopyranoside (IPTG) at an OD600 of 0.6-0.8 and grown for 16 hours at 15C. Cells
were pelleted and resuspended in 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 % Triton, 1 mM EDTA, 1 mM EGTA, 0.1 % 2-mercap-
toethanol, 1 mM Pefabloc, 1 mM benzamidine. Cell lysis was carried out by sonication. After being clarified through centrifugation,
bacterial lysate was incubatedwith Glutathione Agarose (Expedeon) for 2 hours at 4C. The resin bound proteins werewashed exten-
sively with Wash buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.1 mM EGTA, 0.1 % 2-mercaptoethanol), before being eluted with
wash buffer containing 20 mM Glutathione. The purified proteins were dialysed into storage buffer, flash frozen and stored at -80C.
Plasmids generated at the University of Dundee for the present study are available to request on our reagents website (https://
mrcppureagents.dundee.ac.uk/).
METHOD DETAILS
E1/E2/E3 Assay
The E2-E3 reaction consists of recombinant E1 (100 nM), E2 conjugating enzyme (125-250 nM), E3 ligases (250-500 nM) and
0.25 mg/mL BSA in 10 mM HEPES pH 8.5, 10 mM MgCl2 and 1 mM ATP in a total volume of 5 ml. Assays were performed by
dispensing 2.5 mL of enzyme solution into round bottom 384-well plates (Greiner, Stonehouse, UK). Plates were centrifuged at
200 xg and the reactions were incubated at 37C for 30 min. Reactions were initiated by the addition of 2.5 mL substrate solution
containing 10 mM ubiquitin in 5 mM HEPES pH 8.5. For enzyme titration and time course experiments E2/E3 ligases concentrations
ranged from 125 nM to 1000 nM with a maximum reaction time of 120 min. Plates were incubated at 37C for typically 20-60 min
(depending on the activity of E3 ligase used) before being quenched by the addition of 2.5 mL of a 10 % (v/v) trifluoroacetic acid
(TFA) solution. Controls – with only DMSO - where placed on column 23. For the enzyme inactivated controls in columns 24,
2.5 mL of 10 % TFA was manually dispensed prior to addition of the enzyme solution by XRD-384 Automated Reagent Dispenser
(FluidX). 1.05 ml of each reaction were spiked with 150 nl (4 mM) of 15N-labelled ubiquitin (average mass 8,659.3 Da) and 1.2 ml of
7.6 mg/ml 2,5-dihydroxyacetophenone (DHAP) matrix (prepared in 375 ml ethanol and 125 ml of an aqueous 25 mg/ml diammonium
hydrogen citrate).Cell Chemical Biology 25, 1117–1127.e1–e4, September 20, 2018 e2
For E2 activity assays, we pre-incubated the Ube1 activating enzyme (100 nM) with 27 E2 conjugating enzymes at 1000 nM,
500 nM and 250 nM and stopped the reaction with 2% final TFA at different time points.
Compound Library Spotting and Inhibitor Screening
We used a library of 1430 FDA approved compounds from various commercial suppliers with validated biological and pharmacolog-
ical activities. For single concentration screening 5 nL of 10 mM compound solution in DMSOwas transferred into HiBase Low Bind-
ing 384-well flat bottom plates (Greiner bio-one) to give a final screening concentration of 10 mM. Columns 23 and 24 were reserved
for uninhibited and inhibited controls respectively. The uninhibited control contained 5 nL DMSO but no compound, whereas the in-
hibited control contained 5 nL PR-619 but the enzyme was inactivated by pre-treatment with 1.0 % TFA. All compounds and DMSO
were dispensed using an Echo acoustic dispenser (Labcyte, Sunnyvale, USA). For all HTS assays the final DMSO concentration was
0.1 %. For concentration response curves of known HOIP, MDM2 and ITCH inhibitors, a threefold serial dilution was prepared from
10mMcompound solutions in DMSO in 384-well base plates V-Bottom (Labtech). 100 nL of compoundwas transferred into 384-well
round bottom low binding plates using a Mosquito Nanoliter pipetter (TTP Labtech, Melbourn, UK), giving a final concentration range
between 100 mM and 100 nM.
Target Spotting and MALDI Mass Spectrometry Analysis
1,536-well AnchorChip MALDI targets (Bruker, Bremen Germany) were cleaned using 30% acetonitrile and 0.1% TFA and dried un-
der a gentle flow of pure nitrogen. 200 nL matrix/assay mixture was spotted onto the AnchorChip Plates using a Mosquito nanoliter
dispenser (TTP Labtech, Hertfordshire, UK). Spotted targets were air dried prior to MALDI TOF MS analysis. 0.25 ml of the resultant
mixture was then spotted onto a 1,536 microtiter plate MALDI anchor target (Bruker, Bremen, Germany) using a Mosquito liquid
handling robot (TTP Labtech, Melbourn, UK).
All samples were acquired on a Rapiflex MALDI TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) high resolution
MALDI TOF MS instrument with Compass for flexSeries 2.0. Reflector mode was used with optimized voltages for reflector 1
(20.82 kV), reflector 2 (1.085 kV) and reflector 3 (8.8 kV), ion sources (Ion Source 1: 20.0 kV, PIE 2.35 kV) and Pulsed Ion Extraction
(500 ns). Matrix suppression has been set in Deflection mode to suppress matrix components up to 6560 m/z. Samples were run
in automatic mode (AutoXecute, Bruker Daltonics) using the 1,536 spots AnchorChip. Ionization was achieved by a 10-kHz smart-
beam-II solid state laser (run at 5 kHz) with Laser Fuzzy Control switched off, initial Laser Power set on ‘‘from Laser Attenuator’’ and
accumulation parameters set to 4000 satisfactory shots in 500 shot steps. Movement parameters have been set on ‘‘Walk on Spot’’.
Spectra were accumulated by FlexControl software (version 4 Build 9), processed using FlexAnalysis software (version 4 Build 9) and
the sophisticated numerical annotation procedure (‘SNAP’) peak detection algorithm, setting the signal-to-noise threshold at 5. In-
ternal calibration was performed using the ubiquitin peak ([M+H]+ average = 8,659.3).
Data Analysis
Amodifiedmethod for data acquisition was developed for FlexAnalysis Software version 4, using the SNAP algorithm. For area calcu-
lation, the complete isotopic distribution was taken into account. Data output was exported as a.csv file using FlexAnalysis series 4.0
(Build 24) Batch Process (Compass for flexseries 2.0). An in-house script has been used to extract - from the original csv output file -
the data of interest. The script selects the area values of the light and the heavy ubiquitin and reports them in a grid with the same
MALDI target geometry and sample positions within a txt file. Data are further analysed in Microsoft Excel, where plotting of graphs
and IC50 calculation have been performed on Prism 7 software for windows, version 7.02.
For HTS data analysis, data was expressed as Activity % value for each test compound as follows:
Activity %= 100
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where
light
heavy
test is the light ubiquitin signal normalized to the heavy ubiquitin signal associated with the test compound, m
light
heavy
n
is the average of the light ubiquitin signal normalized to the heavy ubiquitin in the no inhibition signal positive controls (reaction in
presence of DMSO only) and m
light
heavy
p is the is the average of the light ubiquitin signal normalized to the heavy ubiquitin of maximum
effect negative control wells (reaction where 2% TFA final has been added before the addition of substrate)
The performance of the assay on each screening plate was evaluated using internal controls to determine robust Z’ values, which
were calculated as follows:
Z0 = 1

3ðsp + sn Þmr mn

Where the means (m) and standard deviations (s) of both the positive (p) and negative (n) controls are reported.e3 Cell Chemical Biology 25, 1117–1127.e1–e4, September 20, 2018
QUANTIFICATION AND STATISTICAL ANALYSIS
MALDI-TOF data output was exported and analysed by an in-house script as reported in the Data Analysis Paragraph. Data were
further analysed in Microsoft Excel, where plotting of graphs and IC50 calculation have been performed on Prism 7 software for
windows.
For linearity curves and HTS data analysis, data was expressed as Activity % value for each test compound following the formula
reported in Data Analysis Paragraph. For IC50s calculation, duplicate experiments were averaged and the standard deviation of the
meanwere calculated using the GraphPad Prism software with a built-in analysis, nonlinear regression (curve-fit), variable slope (four
parameters) curve to determine IC50 values.Cell Chemical Biology 25, 1117–1127.e1–e4, September 20, 2018 e4
